Follicular Lymphoma · line 1 · Rituximab + CHOP (R-CHOP), 6 cycles

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	aggressive
Linked regimen	`REG-R-CHOP`

ID	`IND-FL-1L-RCHOP-AGGRESSIVE`
Type	Indication
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-FL`
Sources	`SRC-ESMO-LYMPHOMA-2025` `SRC-NCCN-BCELL-2025`

Notes

STUB — pending Clinical Co-Lead sign-off. Reuses REG-R-CHOP from DLBCL pathway.

Used By

Algorithms

ALGO-FL-1L - ALGO-FL-1L
ALGO-NLPBL-1L - ALGO-NLPBL-1L
ALGO-NMZL-1L - ALGO-NMZL-1L